The efficacy of a novel compound, (e)-1-(4'-bromo-4-biphenylyl)-1-(4-chlorophenyl)-3-dimethylaminoprop-1-ene against Trypanosoma cruzi in mice.
The biological properties of a novel compound 353C with high activity against Trypanosoma cruzi, are described. The compound was about 10 times and 20 times more effective than either benznidazole or nifurtimox respectively, in producing radical cure in mice. 353C has a long half-life and showed anti-trypanosomal properties when given to mice at weekly intervals.
D000818:Animals; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D014355:Chagas Disease / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D051379:Mice; D009547:Nifurtimox / Q000627:therapeutic use; D009593:Nitroimidazoles / Q000627:therapeutic use; D014344:Trypanocidal Agents / Q000627:therapeutic use*; D014349:Trypanosoma cruzi / Q000187:drug effects*
D001713:Biphenyl Compounds; D009593:Nitroimidazoles; D014344:Trypanocidal Agents; C034352:1-(4'-bromo-4-biphenylyl)-1-(4-chlorophenyl)-3-dimethylaminoprop-1-ene; D009547:Nifurtimox; C009999:benzonidazole